Kiora Pharmaceuticals
KPRX
12 hedge funds and large institutions have $9.31M invested in Kiora Pharmaceuticals in 2020 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 1 closing their positions.
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
25% more capital invested
Capital invested by funds: $7.44M → $9.31M (+$1.87M)
9% more funds holding
Funds holding: 11 → 12 (+1)
0% less ownership
Funds ownership: 0.11% → 0.11% (-0%)
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$45.5K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$13.8K |
| 3 |
AFG
Albion Financial Group
Salt Lake City,
Utah
|
+$1.38K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
-$85.5K |
| 2 |
GSWM
Golden State Wealth Management
Santa Ana,
California
|
-$7K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
-$4.13K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AC
1
Armistice Capital
New York
| $8.95M | – | – | – |
|
2
BlackRock
New York
| $129K | – | – | – |
|
|
3
Vanguard Group
Malvern,
Pennsylvania
| $115K | +$45.5K | +33 | +103% |
|
|
4
Geode Capital Management
Boston,
Massachusetts
| $62K | -$85.5K | -62 | -64% |
|
|
5
UBS Group
Zurich,
Switzerland
| $20K | +$13.8K | +10 | +1,000% |
|
6
US Bancorp
Minneapolis,
Minnesota
| $13K | – | – | – |
|
7
Royal Bank of Canada
Toronto,
Ontario, Canada
| $8K | – | – | – |
|
|
SFP
8
Sterling Financial Planning
Sparta,
New Jersey
| $6K | +$4.13K | +3 | New |
|
|
TRCT
9
Tower Research Capital (TRC)
New York
| $2K | -$4.13K | -3 | -75% |
|
10
Morgan Stanley
New York
| $2K | – | – | – |
|
11
Osaic Holdings
Scottsdale,
Arizona
| $2K | – | – | – |
|
|
AFG
12
Albion Financial Group
Salt Lake City,
Utah
| $1K | +$1.38K | +1 | New |
|
|
GSWM
13
Golden State Wealth Management
Santa Ana,
California
| – | -$7K | -5 | Closed |
|
KPRX Hedge Fund Activity: Q4 2020 in Review
12 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Kiora Pharmaceuticals (KPRX) for Q4 2020, worth a combined $9.31M — up 25% from $7.44M a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new KPRX positions and 1 closed out — a net gain of 1 holder — while 2 added to existing stakes and 2 trimmed.
The largest buyer was Vanguard Group, adding an estimated $45.5K. The largest seller was Geode Capital Management, cutting an estimated $85.5K.
- 12 institutional investors held Kiora Pharmaceuticals (KPRX) as of Q4 2020, up from 11 in Q3 2020.
- Funds reported $9.31M of Kiora Pharmaceuticals stock for Q4 2020, up 25% quarter-over-quarter.
- 2 funds opened new Kiora Pharmaceuticals positions in Q4 2020 and 1 closed out, a net change of +1 holder.
- The largest Kiora Pharmaceuticals buyer in Q4 2020 was Vanguard Group, an estimated $45.5K added.
- The largest Kiora Pharmaceuticals seller in Q4 2020 was Geode Capital Management, an estimated $85.5K sold.
Based on aggregated 13F filings for Q4 2020.